BDBingzhao Du

Bingzhao Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bingzhao Du has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Sang

    Department of Key Laboratory of Viral Diseases Prevention and Treatment of Traditional Chinese Medicine of Henan Province, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

    1 shared publication
  • Feng Zhao

    School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, PR China

    1 shared publication
  • Hexinge Zhang

    School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, PR China

    1 shared publication
  • Jianyong Xing

    China Resources Sanjiu Medical & Pharmaceutical Co, Ltd., Shenzhen 518110, China

    1 shared publication
  • Jiayao Yuan

    School of the First Clinical, Henan University of Chinese Medicine, Zhengzhou 450000, China

    1 shared publication
  • Mingyi Shao

    Department of Gastroenterology, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Potential Mechanisms of Biejiajian Pill in the Treatment of Diabetic Atherosclerosis Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

    by Rong Zhu, Bingzhao Du, Jiayao Yuan, Shuxun Yan, Mingyi Shao, Feng Sang, Qian Bi, Zhongrui Wang, Qian Zhen, Yu Fu

    Background. Biejiajian pill (BJJP), a classical traditional Chinese formula, has been reported that it has an effective treatment for diabetic atherosclerosis in recent years, but its underlying mechanisms remain elusive. The study aimed to explore the potential mechanisms of BJJP on diabetic atherosclerosis by integrating network pharmacology, molecular docking, and molecular dynamics simulation. Methods. The active components of BJJP were collected by TCMSP and TCMID, and then the potential targets were obtained from the SwissTargetPrediction database. The targets related to diabetic atherosclerosis were identified from the GeneCards and OMIM databases. The intersection of the potential targets regulated by active components of BJJP and the targets of diabetic atherosclerosis were common targets, which were visualized by the Venn diagram. The common targets were imported into the STRING database to construct a protein-protein interaction (PPI) network. The network of Medicine-Compound-Target was constructed with Cytoscape 3.7.1 software. GO functional enrichment analysis and KEGG pathway enrichment analysis were performed using the DAVID database and visualized through bioinformatics. The intersecting targets were input into Cytoscape 3.7.1 software, and the Network Analyzer tool was employed to screen out the key targets. Then molecular docking was used to verify the binding affinity between the active compounds and the key targets, and molecular dynamics simulation was used to investigate the stability of the binding models. Results. A total of 81 active components, 186 targets of BJJP, and 4041 targets of diabetic atherosclerosis were obtained. Furthermore, 121 overlapping targets were identified. GO functional enrichment analysis revealed that these targets were correlated with the oxidation-reduction process, negative regulation of apoptotic process, inflammatory response, and other biological processes. The results of the KEGG pathway enrichment analysis showed that the common targets mainly participated in proteoglycans in cancer, PPAR signaling pathway, adherens junction, insulin resistance, HIF-1 signaling pathway, PI3K-Akt signaling pathway, etc. The results of molecular docking confirmed that the core active components in BJJP could bind well to the key targets. Results from molecular dynamics simulation showed that the binding energies of AKT1-Luteolin, MMP9-quercetin, and MMP9-luteolin complexes were 28.93kJmol−1, 37.12kJmol−1, and 62.91kJmol−1, respectively. Conclusion. The study revealed that BJJP is characterized as multicomponent, multitarget, and multipathway to treat diabetic atherosclerosis, which is helpful to provide ideas and a basis for pharmacological research and clinical application in the future.


  • Ilex asprella aqueous extracts exert in vivo anti-inflammatory effects by regulating the NF-κB, JAK2/STAT3, and MAPK signaling pathways

    by Xinyao Yang, Xiaoli Gao, Bingzhao Du, Feng Zhao, Xiao Feng, Hexinge Zhang, Zhixiang Zhu, Jianyong Xing, Zhengzhou Han, Pengfei Tu, et al.